191, p21 obtained Ht phosphorylation of Bcl-2 and apoptosis in human cells of the breast, 192 obtained Ht the expression of a NaI symporter in thyroid carcinoma cells Serving AT7519 for resensitization m Resembled thyroid cancer ndigen of radio-best and 193 Facilitate apoptosis mediated by active caspase-8 and down regulates c FLIP protein.194 sequential treatment with 5 azaDc detection of cancer cells by T cells, the cells specific for the antigen 1B testicular cancer as an option for immunotherapy195 or induced tissue factor pathway inhibitor expression in two cancer .196 first Kardiotoxizit t was by the administration Zeitpl ne convenient but cardiac monitoring is gel st w especially performed during the clinical examination. Studies in CLL and AML concentrations were correlated with apoptosis induction and inhibition of HDAC.
Romidepsin combination of drugs and DNA demethylating by ETO positive leukemia Premiums cells.197 potentiates A genetic signature specific sensitivity Romidepsin was reported.198 The recent approval of Romidepsin in CTCL, all ver the first clinical trials Ffentlicht this GDC-0941 disease can not be addressed. 199 200 Romidepsin induces the expression of the MDR 1 in various cancer cell lines. A Phase I study in advanced countries L Stated incurable cancers201 that further clinical trials are required. Neoplasms202 for advanced or refractory Ren, half-life is used is 8.1 hours. In the CSF and has AML203 intravenously Se treatment not answer. Romidepsin effectively inhibits HDAC in vivo in patients with CLL and AML, but future studies should examine other routes of administration.
In refractory Ren or recurrent solid tumors204 DLT were not with Ver Asymptomatic changes in troponin or signs of dysfunction, transient sinus syndrome and Hypokalz Associated chemistry. For MDS and AML205 intravenously Se administration showed no significant cardiac toxicity T. Romidepsin treatment with acceptable toxicity can t be given shortly. Gastrointestinal symptoms and fatigue seemed to treat limited after several cycles. Phase II study of refractory renal cell carcinoma cancer206, IV was classic, but severe toxicity How it is Two patients developed a ridiculed Ngertes QT interval, one patient developed grade 3 atrial fibrillation and tachycardia, and there was a pl Tzlichen death.
In metastatic neuroendocrine tumors207 adverse events were ventricular Re tachycardia and ridiculed Ngerte QT, dinner pl entered Tzlichen death ended the study early. Romidepsin must assess serious cardiac adverse effects and risks comprehensively. In lung cancer, 208 Romidepsin was not appropriate. This study presents a low profile in the expression of the genes. Conclusion A number of clinical trials have been completed and others are currently so many HDACi single agent and in combination with chemotherapy or radiation therapy for the treatment of several hours Dermatological and solid tumors with promising early results. Vorinostat is the most established and HDACi was ap